Review clinical presentations from esteemed colleagues on challenging mNSCLC cases*
Leading oncologists identify patients who may be appropriate for CYRAMZA + docetaxel

Roy S. Herbst, MD, PhD, presents a challenging clinical case of progressing mNSCLC
Review full case presentation:
57-Year-Old Female With Stage IV Non-Small Cell Lung Cancer Progressing on Platinum-based Chemotherapy
Patient Rapidly Progressed† Within 12 Weeks
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program
Yale Comprehensive Cancer Center, Yale School of Medicine, Smilow Cancer Hospital, New Haven, Connecticut

Corey J. Langer, MD, FACP, presents a challenging clinical case of progressing mNSCLC
Review full case presentation:
64-Year-Old Female with Stage IV Non-Small Cell Lung Cancer Progressing on Platinum-based Chemotherapy
Patient Rapidly Progressed† Within 12 Weeks
Corey J. Langer, MD, FACP
Professor of Medicine Hematology/Oncology Division - University of Pennsylvania, Philadelphia, Pennsylvania
These are hypothetical patient cases based on the authors' clinical experience with CYRAMZA in combination with docetaxel for mNSCLC.
*These clinical case presentations have been sponsored by Eli Lilly and Company.
†Rapidly progressing disease is defined as time to progression within 12 weeks after starting initial platinum-based treatment.1
mNSCLC=metastatic non-small cell lung cancer.
Reference: 1. Reck M, Shepherd F, Pérol M, et al. Effects of second-line ramucirumab after rapid time to progression on first-line therapy: subgroup analysis of REVEL in advanced non-small cell lung cancer. Oral presentation presented at: IASLC 18th World Conference on Lung Cancer; October 15-18, 2017; Yokohama, Japan.